109022 20230519145344.0 doi 10.1007/s12020-020-02560-6 sideral 121618 ART-2021-121618 eng de Arriba Munoz, A. Universidad de Zaragoza (orcid)0000-0002-2865-5813 Impact of adherence on growth response during the first 2 years of growth hormone treatment 2021 Access copy available to the general public Unrestricted Purpose Adherence to growth hormone (GH) treatment impacts clinical outcomes. The aim of this study is to assess the impact of adherence to rhGH treatment (2 years) on auxological outcomes. Methods Multicentric, retrospective observational study in rhGH-naive GHD/SGA children treated with Saizen (R) during >= 2 years. Growth response was assessed by evaluating the change in height standard deviation score (Delta H SDS) and the index of responsiveness (IoR). Adherence was monitored using EasyPod (TM) Connect device. Results A total of 110 patients (3 Spanish centers) were evaluable (GHD n = 76, SGA n = 34). Adherence was 95.6 and 93.9% (year 1, 2). SGA and GHD children showed an increase of 0.6 cm/year and 1.1 cm/year for each 10% adherence modification. Lower adherence was observed in patients with lower pretreatment height velocity (HV) and in patients whose parents had a lower level of education. A positive correlation between index of responsiveness (IoR) during the first and second years with HV SDS during the second year and between IoR2 and adherence (year 1, 2) was observed. The frequency of patients with HV > 1 SD was higher (p = 0.025) among patients with adherence >90%. The best model to predict the height gain(cm) reaching an adjusted R squared of 0.489 involved percentage of adherence, Tanner stage, pretreatment HV, dose of rhGH, and whether the treatment was initiated before or after puberty. Conclusions Adherence during the first 2 years of response was very high >90% and showed a negative association with age, pretreatment HV and treatment duration and a positive correlation with the level of parent education. info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.925 2021 ENDOCRINOLOGY & METABOLISM 79 / 147 = 0.537 2021 Q3 T2 0.873 2021 Endocrinology, Diabetes and Metabolism 2021 Q2 Endocrinology 2021 Q2 6.0 2021 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Cancela Muñiz, V. Alcon Saez, J.J. Beisti, A. Llovet, E. Labarta Aizpun, J.I. Universidad de Zaragoza (orcid)0000-0003-2832-2266 1011 670 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Pediatría 72 (2021), 513–523 Endocrine (Basingstoke) ENDOCRINE 1355-008X 697175 http://zaguan.unizar.es/record/109022/files/texto_completo.pdf Postprint 2002149 http://zaguan.unizar.es/record/109022/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:109022 articulos driver 2023-05-18-13:18:34 ARTICLE